44
Participants
Start Date
October 25, 2023
Primary Completion Date
June 24, 2024
Study Completion Date
June 24, 2024
VH4004280
VH4004280 was administered as tablets orally at Day 1.
VH4011499
VH4011499 was administered as tablets orally at Day 1 and Day 6.
VH4004280 Matching Placebo
VH4004280 Matching Placebo was administered as tablets orally at Day 1.
VH4011499 Matching Placebo
VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
Antiretroviral therapy
Antiretroviral therapy was administered as available and as per investigator's recommendation.
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Marseille
GSK Investigational Site, Milan
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, DeLand
GSK Investigational Site, Nantes
GSK Investigational Site, Guadalajara
GSK Investigational Site, Cologne
GSK Investigational Site, Paris
GSK Investigational Site, Bakersfield
GSK Investigational Site, Newark
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Ciudad Autonoma de Bueno
GSK Investigational Site, Montreal
GSK Investigational Site, Mexico City
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, London
Lead Sponsor
ViiV Healthcare
INDUSTRY